Seroprevalence to Hepatitis B Virus among Prisoners Taking into Account Age, HIV Status, and Injection Drug Use

Relevance. Prisoners have a high risk of contracting hemocontact viral infections (including HIV, viral hepatitis B and C, etc.), which creates an additional infectious burden on the entire population living in the territory. Aims. To study the level of immune protection to viral hepatitis B in risk groups (age, HIV status, and injection drug use) of persons held in places of detention to identify those in need of vaccine prophylaxis. Materials & Methods. 343 blood serum samples obtained in 2021 from males with negative HBsAg status were studied. Anti-HBs antibodies to HBsAg were determined using a set of reagents “VectoHBsAg-antibodies” (Vector-Best, Russia). Results and discussion. The protective titer of anti-HBs antibodies was detected in 44.0% (n = 151) of cases, and was absent in 56.0% of the subjects. At the same time, anti-HBs was significantly more often detected in people living with HIV/AIDS (p = 0.038), injecting drug users (p = 0.002), as well as young people born after 1984 (p = 0.019). Conclusion. The lack of a significant level of collective immunity among prisoners, primarily the older age group before 1984, their risky behaviors (sexual, injection) indicate the need for active identification of seronegative persons serving sentences in places of detention and specific immunoprophylaxis.

1. Shamsheva OV, Kochetova EO, Polesko IV, et al. Characteristics of post-vaccination immunity in students vaccinated against hepatitis B in the first year of life. Children infections. 2021;20(3):29–32 (In Russ). doi: 10.22627/2072-8107-2021-20-3-29-32

2. Paraskiv AL. Analysis of the chronic hepatitis B morbidity in conditions of mass vaccination in the republic of Moldova. Zhurnal MediAl’ 2020;26(2):24–29 (In Russ). doi: 10.21145/2225-0026-2020-2-24-29

3. Vyaltsin SV, Klyueva KA, Plotnikova EG, et al. Morbidity of the population in the Orenburg region with viral hepatitis for the period from 2016–2020. Public Health. 2023;3(2):47–55 (In Russ). doi: 10.21045/2782-1676-2023-3-2-47-55

4. World Health Organization. Interim guidance for country validation of viral hepatitis elimination. Geneva: WHO. 2021. 96 p.

5. Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023;8(4):332–342. doi: 10.1016/S2468-1253(22)00386-7

6. Kuzin SN, Semenenko TA, Klushkina VV, et al. Herd Immunity to Hepatitis B in the Russian Federation in 2017–2019. Epidemiology and Vaccinal Prevention. 2022;21(2):29–37 (In Russ). doi: 10.31631/2073-3046-2022-21-2-29-37.

7. Methodological guidelines MG 3.1.2943-11 «Organizacija i provedenie serologicheskogo monitoringa sostojanija kollektivnogo immuniteta k infekcijam, upravljaemym sredstvami specificheskoj pro- filaktiki (difterija, stolbnjak, kokljush, kor’, krasnuha, jepidemicheskij parotit, poliomielit, gepatit V)». Available at: https://base.garant.ru/70102912/. Accessed: 23 Dec 2023 (In Russ).

8. Yrysova MB. Postvakcinal’nyj skrining immunologicheskoj jeffektivnosti vakcinacii protiv gepatita V grupp riska inficirovanija (medrabotniki, zakljuchennye) v gorode Bishkek. Nauka I Novye Tehnologii. 2009;(7):41–43. (In Russ).

9. Medunitsyn NV, Olefir YuV, Merkulov VA, et al. Vaccination contribute to the development of personal and herd immunity. BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(4):195–207 (In Russ).

10. Ashby B, Best A. Herd immunity. Current biology. 2021;31(4):R174–R177. doi: 10.1016/j.cub.2021.01.006

11. Goyal A, Murray JM. The Impact of Vaccination and Antiviral Therapy on Hepatitis B and Hepatitis D Epidemiology. PLoS ONE. 2014;9(10):e110143. doi: 10.1371/journal.pone.0110143

12. Shapiyeva NT, Ponezheva ZhB, Makashova V, et al. Modern aspects of chronic hepatitis B. Lechaschi Vrach. 2019;(5):82 (In Russ).

13. Poljanina AV, Bystrova TN. Molekuljarno-jepidemiologicheskaja harakteristika virusa gepatita B v uslovijah massovoj vakcinoprofilaktiki. Zhurnal MediAl’. 2019;24(2):10–39 (In Russ). doi: 10.21145/2225-0026-2019-2-10-39.

14. Kamarulzaman A, Reid SE, Schwitters A, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. The Lancet. 2016;388(10049):1115–1126. doi: 10.1016/S0140-6736(16)30769-3

15. Anufrieva EV, Serikova EN, Ostankova YuV, et al. The structure of some blood-borne infections distribution among persons from penitentiary institutions the markers. HIV Infection and Immunosuppres- sive Disorders. 2023;15(3):95–104 (In Russ). doi: 10.22328/2077-9828-2023-15-3-95-104

16. Singh KP, Crane M, Audsley J et al. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS. 2017;31(15):2035–2052. doi: 10.1097/QAD.0000000000001574

17. Ponomarev SB, Sterlikov SA, Mikhaylov АYu. HIV Situation in the Penitentiary System of the Russian Federation. Tuberculosis and Lung Diseases. 2022;100(3):39–45 (In Russ), doi: 10.21292/2075-1230-2022-100-3-39-45

18. Hammer Ø., Harper D.A. Past: paleontological statistics software package for educaton and data anlysis. Palaeontologia electronica 2001;4(1):1.

19. Dan-Nwafor CC, Adeoye I, Aderemi K, et al. Serological markers and risk factors associated with Hepatitis B virus infection among Federal Capital Territory prison inmates, Nigeria: Should we be con- cerned? PLOS ONE. 2021;16(3):e0248045. doi: 10.1371/journal.pone.0248045

20. Rezende GR, Lago BV, Puga MA, et al. Prevalence, incidence and associated factors for HBV infection among male and female prisoners in Central Brazil: A multicenter study. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2020;96:298–307. doi: 10.1016/j.ijid.2020.04.019

21. Eremeeva ZhG., Fazylov VH., Turaev RG., et al. Postvakcinal’nyj immunitet k gepatitu B v gruppe riska. Vestnik gematologii. 2018. T. 14, № 4.– S. 26–26 (In Russ).

22. Asratyan АA, Musina ЕE, Novikova YuB, et al. Evaluation of strength and duration of post-vaccination immunity against hepatitis B of medical personnel in a major narcological hospital. Epidemiology and Vaccinal Prevention. 2011;58(3):64–69 (In Russ).

23. Jesaulenko E.V., Ljalina L.V., Trifonova G.F, et al. Virusnye gepatity v Rossijskoj Federacii. Analiticheskij obzor. Vypusk 11. Saint-Petersburg: Saint-Petersburg Pasteur Institute; 2018. 112 p (in Russ).

24. Corcorran MA, Kim N. Chronic hepatitis B and HIV coinfection. Top Antivir Med. 2023;31(1):14–22. PMID: 37018732

25. Budd J, Robertson R, Elton R. Hepatitis B vaccination and injecting drug users. The British Journal of General Practice: The Journal of the Royal College of General Practitioners. 2004;54(503):444–447. PMID: 15186567

26. Haussig JM, Nielsen S, Gassowski M et al. A large proportion of people who inject drugs are susceptible to hepatitis B: Results from a bio-behavioural study in eight German cities. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2018;66:5–13. doi: 10.1016/j.ijid.2017.10.008

27. Palmateer NE, Goldberg DJ, Munro A et al. Association between universal hepatitis B prison vaccination, vaccine uptake and hepatitis B infection among people who inject drugs. Addiction. 2018;113(1):80–90. doi: 10.1111/add.13944